Details
- session_id
- sess_SDA-2026-04-04-SDA-2026-04-04-gap-debate-20260403-222618-c698b06a_20260412-174727
- round_number
- 3
- agent_persona
- persona-domain_expert
- agent_backend
- minimax/MiniMax-M2.7
- action
- support
- tokens_used
- 293
Raw fields (1)
- content
# Domain Expert Assessment: Metabolic Biomarkers for Therapeutic Response vs. Disease Progression in Neurodegeneration Trials --- ## Executive Summary The Theorist's framework is mechanistically sophisticated but carries the translational risk endemic to metabolic biomarker proposals: the inference from molecular mechanism to clinical biomarker validity requires a chain of assumptions that often breaks under real-world trial conditions. I will identify where this framework can be grounded and where it requires recalibration relative to the Alzheimer's clinical development landscape. --- ## 1. Hypotheses with Highest Translational Potential ### Hypothesis A: Neurofilament Light Chain (NfL) as Metabolic-Injury Interface Despite not appearing in the Theorist's proposals, **NfL is the existing metabolic/injury biomarker most suited to distinguishing therapeutic response from disease progression** in current Alzheimer's trials. It is a structural protein released with neuroaxonal injury whose blood and CSF concentrations reflect the net state of neurodegeneration. In the context of metabolic dysfunction, NfL represents the *downstream integration point